Wedbush analyst Laura Chico raised the firm’s price target on Ovid Therapeutics (OVID) to $7 from $5 and keeps an Outperform rating on the shares. The firm highlights multiple updates in the Q4 update, including a $60M private placement, 7mg OV329 data and expansion of the OV329 development program into Tuberous Sclerosis Complex and Infantile Spasms. Separately, KCC2 efforts also remain on track with an upcoming R&D event on April 14 to further describe the platform.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines
- Ovid Therapeutics price target raised to $5 from $3 at Roth Capital
- Ovid Therapeutics: Advancing OV329 Pipeline, De‑Risked Differentiation, and Strong Cash Runway Support Buy Rating
- Midday Fly By: General Mills reports downbeat Q3, Macy’s reports Q4 beat
- PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention